MA28691B1 - Procede de traitement du cancer - Google Patents

Procede de traitement du cancer

Info

Publication number
MA28691B1
MA28691B1 MA29575A MA29575A MA28691B1 MA 28691 B1 MA28691 B1 MA 28691B1 MA 29575 A MA29575 A MA 29575A MA 29575 A MA29575 A MA 29575A MA 28691 B1 MA28691 B1 MA 28691B1
Authority
MA
Morocco
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
MA29575A
Other languages
English (en)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA28691B1 publication Critical patent/MA28691B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA29575A 2004-06-03 2006-12-28 Procede de traitement du cancer MA28691B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02

Publications (1)

Publication Number Publication Date
MA28691B1 true MA28691B1 (fr) 2007-06-01

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29575A MA28691B1 (fr) 2004-06-03 2006-12-28 Procede de traitement du cancer

Country Status (14)

Country Link
US (1) US20100063074A1 (fr)
EP (1) EP1768963A4 (fr)
JP (1) JP2008501690A (fr)
KR (1) KR20070030240A (fr)
AU (1) AU2005251722B2 (fr)
BR (1) BRPI0511754A (fr)
CA (1) CA2569132A1 (fr)
IL (1) IL179359A0 (fr)
MA (1) MA28691B1 (fr)
MX (1) MXPA06013635A (fr)
NO (1) NO20066077L (fr)
NZ (1) NZ551622A (fr)
RU (1) RU2006142420A (fr)
WO (1) WO2005120504A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661223A1 (fr) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. Derives de 4-aminoquinazoline et leurs procedes d'utilisation
WO2009137714A2 (fr) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Formes de ditosylate de lapatinib et procédés pour leur préparation
WO2010017387A2 (fr) * 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Intermédiaires de lapatinib
EP2158912A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (fr) * 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
EP3615067A1 (fr) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Traitement des cancers positifs à her2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2413134C (fr) * 2000-06-30 2010-05-11 Glaxo Group Limited Composes ditosylates de quinazoline
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
CA2482591A1 (fr) * 2002-04-16 2003-10-30 Astrazeneca Ab Therapie combinee de traitement du cancer
AU2003235470A1 (en) * 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
EP1534674A4 (fr) * 2002-08-02 2007-11-28 Immunogen Inc Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
WO2005120504A2 (fr) 2005-12-22
NO20066077L (no) 2007-01-31
WO2005120504A3 (fr) 2006-02-23
IL179359A0 (en) 2007-03-08
EP1768963A4 (fr) 2009-06-10
EP1768963A2 (fr) 2007-04-04
AU2005251722B2 (en) 2009-11-12
AU2005251722A1 (en) 2005-12-22
MXPA06013635A (es) 2007-02-28
US20100063074A1 (en) 2010-03-11
BRPI0511754A (pt) 2008-01-02
RU2006142420A (ru) 2008-07-20
NZ551622A (en) 2010-01-29
JP2008501690A (ja) 2008-01-24
KR20070030240A (ko) 2007-03-15
CA2569132A1 (fr) 2005-12-22

Similar Documents

Publication Publication Date Title
EP1667680A4 (fr) Methodes combinees de traitement du cancer
EP1830869A4 (fr) Procede de traitement ou prophylaxie
EP1732650A4 (fr) Composition et methode de traitement du cancer
EP1613308A4 (fr) Procedes de traitement du cancer
EP1991230A4 (fr) Méthodes de traitement du cancer
EP1663259A4 (fr) Compositions et methodes de traitement du cancer
EP1926446A4 (fr) Systeme et procede pour generer des traces de traitement
EP1587519A4 (fr) Traitement du cancer par le 2-desoxyglucose
IL185581A0 (en) Method of treating actinic keratosis
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
EP1863507A4 (fr) Compositions et procede de traitement de l'acne
EP2056855A4 (fr) Méthode de traitement de photodermatoses
EP1838714A4 (fr) Procedes de traitement de la douleur
EP1677816A4 (fr) Methode de traitement
EP2124547A4 (fr) Procédé de traitement du cancer
EP1819639A4 (fr) Procede de traitement de nebulisation
PT2099446E (pt) Método de tratamento de doença inflamatória intestinal
FR2875236B1 (fr) Procede et installation pour le traitement de dso
FR2876047B1 (fr) Traitement de polluants par phytolixiviation
EP2161354A4 (fr) Agent de traitement de surface de cuivre et procédé de traitement de surface
EP1707914A4 (fr) Procede de traitement par explosion
MA28901B1 (fr) Methode de traitement de cancers
EP1833511A4 (fr) Methode de traitement du cancer du cerveau
EP2068911A4 (fr) Procédés de traitement du cancer
FI20070455A0 (fi) Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon